Cachexia is a severe complication of cancer that adversely affects the course of the disease,
with currently no effective treatments. It is characterized by a progressive atrophy of skeletal …

Therapy-related acute myeloid leukemia (t-AML), defined as AML arising from prior
cytotoxic, radiation, or immunosuppressive therapy for an unrelated disease, accounts for …

Background Daunorubicin and cytarabine are used as standard induction chemotherapy for
patients with acute myeloid leukaemia. CPX-351 is a dual-drug liposomal encapsulation of …

Background Clonal hematopoiesis of indeterminate potential (CHIP) is a novel
cardiovascular disease (CVD) risk factor in individuals without acute myeloid leukemia …

Acute myeloid leukemia (AML) is a common and catastrophic hematological neoplasm with
high mortality rates. Conventional therapies, including chemotherapy, hematopoietic stem …

Mutations in NPM1, also known as nucleophosmin-1, B23, NO38, or numatrin, are seen in
approximately one-third of patients with acute myeloid leukaemia (AML). A plethora of …

Advances in cancer treatment have significantly improved the survival of patients with
cancer, but, unfortunately, many of these treatments also have long‐term complications …

Simple Summary This is a scoping study aiming to extensively assess and explore the
degree of cardiotoxicity in patients with Acute Myeloid Leukemia (AML) that can be caused …

Background The clinical application of anthracycline chemotherapy is hindered due to the
cumulative dose-dependent cardiotoxicity followed by the oxidative stress initiated during …

Cardiovascular disease (CVD) and cancer are leading causes of death globally, particularly
among the rapidly growing population of older adults (OAs). CVD is a leading cause of …